



Preliminary review of menstrual blood-derived cell therapy to support astronauts in long-term space missions

Marion Dugué – TU Delft, MSc student

IN COOPERATION WITH





OUTLINE

Motivation

Pipeline

Key facts > Naïve calculations

Future research





MOTIVATION

•



WASTE

RESOURCE



PIPELINE

•

•

•



2. Transfer to onboard lab



SVA

Isolation of MenSC
Cultivation/proliferation
(Optional) Storage

6. Injection



WHAT WE KNOW

•

•

7



Mesenchymal stem cells

Embryonic stem cells

Menstrual-blood derived stem cells (MenSC):

- Plastic adherent
- Don't express class II histocompatibility complex (MHC)
- Duplication rate (on Earth) of 19.4h



Menstrual blood key facts

Menstruating astronauts 35 years old average

Duration Average periods during 5-7 days for a cycle of around 28 days

Quantity 60ml of menstrual fluid per period



MenSC/Stem cell key facts

- Content
 - 600 CFU-F per ml of menstrual fluid
- Duplication rate of MenSC 19.4h
- Injection requirements
 - Local injection
 - \sim 20 to 50 million stem cells
 - IV injection
 - \sim 70 to 190 million.



<u>Cell count from one menstruation cycle as a function of days</u>



NAIVE CALCULATIONS

•



Assumption #1:

Periods in space are analog to those on Earth

Assumption #2: Microgravity cell mechanisms analog to those on Earth

Assumption #3:

Stem cell therapy is appropriate for crewed missions



IS IT FEASIBLE?



•



Insights from this prelim. review

- Naively, quantities and timeframe
- More research needed
 - Periods in micro-gravity (quantity, quality but also comfort and psychology of the menstruating astronauts)
 - MenSC mechanisms in space
 - Development of required apparatus (e.g micro-gravity menstrual cup, isolation of MenSC)



THANK YOU.

Marion Dugué

marion-dugue@live.fr https://www.linkedin.com/in/mariondugue/

www.melissafoundation.org

Follow us on social networks

f in 💙 🖸 🕑







